# Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

> **NCT02458287** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 299 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **BIOLOGICAL:** Bococizumab 150mg
- **BIOLOGICAL:** Bococizumab 75mg
- **BIOLOGICAL:** Bococizumab 150mg placebo
- **BIOLOGICAL:** Bococizumab 75mg placebo

## Key facts

- **NCT ID:** NCT02458287
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 299 (ACTUAL)
- **Last updated:** 2017-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02458287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02458287, "Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02458287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*